In medical news:

FDA advisors voted 22-1 against approval of an abuse-deterrent formulation of extended-release oxycodone that was pitched as being an improvement on OxyContin. The majority of panelists at the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) said they rejected Rexista because developer Intellipharma didn’t conduct the types of studies advised by FDA’s abuse-deterrent opioid development guidelines, according to a MedPage Today report.

Read more here.

Leave a Comment

Your email address will not be published. Required fields are marked *